Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials

Journal of Immunological Methods

Volumn 409, Issue , 2014, Pages 107-116

  Sambor, Anna ^a   Garcia, Ambrosia ^b,c   Berrong, Mark ^c   Pickeral, Joy ^c   Brown, Sara ^b   Rountree, Wes ^b,c   Sanchez, Ana ^b,c   Pollara, Justin ^c   Frahm, Nicole ^d   Keinonen, Sarah ^b,c   Kijak, Gustavo H ^e   Roederer, Mario ^f   Levine, Gail ^a   D'Souza, M Patricia ^a   Jaimes, Maria ^g   Koup, Richard ^f   Denny, Thomas ^b,c   Cox, Josephine ^h   Ferrari, Guido ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d USA   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g BD Technologies   (United States)

^h INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

Cryopreservation; Peripheral blood mononuclear cells; Repository

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; VIRUS ANTIGEN;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL FUNCTION; CELL VIABILITY; CLINICAL DATA REPOSITORY; CLINICAL TRIAL (TOPIC); CRYOPRESERVATION; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOASSAY; INFLUENZA VIRUS; INTRACELLULAR CYTOKINE STAINING; LEUKAPHERESIS; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; REVIEW; SAMPLING; T LYMPHOCYTE SUBPOPULATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS 1; ORTHOMYXOVIRIDAE;

CRYOPRESERVATION; PERIPHERAL BLOOD MONONUCLEAR CELLS; REPOSITORY;

ADOLESCENT; ADULT; AIDS VACCINES; BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; CELL SURVIVAL; COOPERATIVE BEHAVIOR; CRYOPRESERVATION; CYTOKINES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC TESTS; INTERFERON-GAMMA RELEASE TESTS; INTERNATIONAL COOPERATION; LABORATORY PROFICIENCY TESTING; LEUKAPHERESIS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; QUALITY INDICATORS, HEALTH CARE; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906099142     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.04.005     Document Type: Review

References (31)

1. Alter G., Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J. Intern. Med. 2009, 265:29.
2. Bonsignori M., Alam S.M., Liao H.-X., Verkoczy L., Tomaras G.D., Haynes B.F., Moody M.A. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol. 2012, 20:532.
3. Britten C.M., Janetzki S., Butterfield L.H., Ferrari G., Gouttefangeas C., Huber C., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J.M., O'Donnell-Tormey J., Odunsi K., Old L.J., Ottenhoff T.H.M., Ottensmeier C., Pawelec G., Roederer M., Roep B.O., Romero P., van der Burg S.H., Walter S., Hoos A., Davis M.M. T cell assays and MIATA: The essential minimum for maximum impact. Immunity 2012, 37:1.
4. Bull M., Lee D., Stucky J., Chiu Y.-L., Rubin A., Horton H., McElrath M.J. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 2007, 322:57.
5. Cox J.H., Ferrari G., Kalams S.A., Lopaczynski W., Oden N., D'souza M.P. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses 2005, 21:68. Elispot Collaborative Study Group.
6. Currier J.R., Kuta E.G., Turk E., Earhart L.B., Loomis-Price L., Janetzki S., Ferrari G., Birx D.L., Cox J.H. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 2002, 260:157.
7. Ferrari G., Pollara J., Kozink D., Harms T., Drinker M., Freel S., Moody M.A., Alam S.M., Tomaras G.D., Ochsenbauer C., Kappes J.C., Shaw G.M., Hoxie J.A., Robinson J.E., Haynes B.F. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 2011, 85:7029.
8. Gill D.K., Huang Y., Levine G.L., Sambor A., Carter D.K., Sato A., Kopycinski J., Hayes P., Hahn B., Birungi J., Tarragona-Fiol T., Wan H., Randles M., Cooper A.R., Ssemaganda A., Clark L., Kaleebu P., Self S.G., Koup R., Wood B., McElrath M.J., Cox J.H., Hural J., Gilmour J. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 2010, 5:e14330.
9. Hansen S.G., Sacha J.B., Hughes C.M., Ford J.C., Burwitz B.J., Scholz I., Gilbride R.M., Lewis M.S., Gilliam A.N., Ventura A.B., Malouli D., Xu G., Richards R., Whizin N., Reed J.S., Hammond K.B., Fischer M., Turner J.M., Legasse A.W., Axthelm M.K., Edlefsen P.T., Nelson J.A., Lifson J.D., Fruh K., Picker L.J. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 2013, 340:1237874.
10. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.-X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275.
11. Horton H., Thomas E., Stucky J., Frank I., Moodie Z., Huang Y., Chiu Y., Mcelrath M., Derosa S. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods 2007, 323:39.
12. Janetzki S., Hoos A., Melief C.J.M., Odunsi K., Romero P., Britten C.M. Structured reporting of T cell assay results. Cancer Immun. 2013, 13:13.
13. Lamoreaux L., Roederer M., Koup R. Intracellular cytokine optimization and standard operating procedure. Nat. Protoc. 2006, 1:1507.
14. Li F., Malhotra U., Gilbert P.B., Hawkins N.R., Duerr A.C. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006, 24:6893.
15. Locci M., Havenar-Daughton C., Landais E., Wu J., Kroenke M.A., Arlehamn C.L., Su L.F., Cubas R., Davis M.M., Sette A., Haddad E.K., Poignard P., Crotty S. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013, 39:758.
16. Makedonas G., Betts M.R. Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol. Rev. 2010, 239:109.
17. Olemukan R.E., Eller L.A., Ouma B.J., Etonu B., Erima S., Naluyima P., Kyabaggu D., Cox J.H., Sandberg J.K., Wabwire-Mangen F., Michael N.L., Robb M.L., de Souza M.S., Eller M.A. Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting. Clin. Vaccine Immunol. 2010, 17:910.
18. Ozaki D.A., Gao H., Todd C.A., Greene K.M., Montefiori D.C., Sarzotti-Kelsoe M. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS One 2012, 7:e30963.
19. Perfetto S.P., Ambrozak D., Nguyen R., Chattopadhyay P., Roederer M. Quality assurance for polychromatic flow cytometry. Nat. Protoc. 2006, 1:1522.
20. Perfetto S.P., Chattopadhyay P.K., Lamoreaux L., Nguyen R., Ambrozak D., Koup R.A., Roederer M. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J. Immunol. Methods 2006, 313:199.
21. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47:401.
22. Plotkin S.A. Complex correlates of protection after vaccination. Clin. Infect. Dis. 2013, 56:1458.
23. Pollara J., Hart L., Brewer F., Pickeral J., Packard B.Z., Hoxie J.A., Komoriya A., Ochsenbauer C., Kappes J.C., Roederer M., Huang Y., Weinhold K.J., Tomaras G.D., Haynes B.F., Montefiori D.C., Ferrari G. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011, 79A:603.
24. Reimann K.A., Chernoff M., Wilkening C.L., Nickerson C.E., Landay A.L., The ACTG immunology advanced technology laboratories Preservation of Lymphocyte Immunophenotype and Proliferative Responses in Cryopreserved Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Donors: Implications for Multicenter Clinical Trials. Clin. Vaccine Immunol. 2000, 7:352.
25. Russell N.D., Hudgens M.G., Ha R., Havenar-Daughton C., McElrath M.J. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J. Infect. Dis. 2003, 187:226.
26. Sarzotti-Kelsoe M., Cox J., Cleland N., Denny T., Hural J., Needham L., Ozaki D., Rodriguez-Chavez I.R., Stevens G., Stiles T., Tarragona-Fiol T., Simkins A. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med. 2009, 6:e1000067.
27. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276:6591.
28. Walker B., McMichael A. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2012, 2:a007054.
29. Walsh P.N., Friedrich D.P., Williams J.A., Smith R.J., Stewart T.L., Carter D.K., Liao H.-X., McElrath M.J., Frahm N., NIAID HIV Vaccine Trials Network Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. J. Immunol. Methods 2013, 394:84.
30. Weinberg A., Song L.-Y., Wilkening C., Sevin A., Blais B., Louzao R., Stein D., Defechereux P., Durand D., Riedel E., Raftery N., Jesser R., Brown B., Keller M.F., Dickover R., McFarland E., Fenton T. Pediatric ACTG Cryopreservation Working Group, 2009. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin. Vaccine Immunol. 2009, 16:1176.
31. Weinberg A., Song L.Y., Wilkening C.L., Fenton T., Hural J., Louzao R., Ferrari G., Etter P.E., Berrong M., Canniff J.D., Carter D., Defawe O.D., Garcia A., Garrelts T.L., Gelman R., Lambrecht L.K., Pahwa S., Pilakka-Kanthikeel S., Shugarts D.L., Tustin N.B. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J. Immunol. Methods 2010, 363:42.